Compare HUN & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | SRPT |
|---|---|---|
| Founded | 1970 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2005 | 1997 |
| Metric | HUN | SRPT |
|---|---|---|
| Price | $11.73 | $23.85 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 29 |
| Target Price | $10.23 | ★ $26.23 |
| AVG Volume (30 Days) | ★ 4.2M | 2.8M |
| Earning Date | 02-17-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,780,000,000.00 | $2,413,715,000.00 |
| Revenue This Year | N/A | $13.72 |
| Revenue Next Year | $3.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.15 |
| 52 Week Low | $7.30 | $10.42 |
| 52 Week High | $18.53 | $128.75 |
| Indicator | HUN | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 73.03 | 64.06 |
| Support Level | $9.90 | $20.86 |
| Resistance Level | $11.32 | $24.12 |
| Average True Range (ATR) | 0.45 | 0.95 |
| MACD | 0.11 | 0.16 |
| Stochastic Oscillator | 94.96 | 92.22 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Materials. It derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.